Cargando…

A Phase 2 open label study of ledipasvir/sofosbuvir for 12 weeks in subjects with hepatitis B virus infection

Retrospective data showed that when we administered ledipasvir/sofosbuvir (LDV/SOF) to patients with hepatitis B and C coinfection, there was a modest reduction in hepatitis B surface antigen (HBsAg). Therefore, we hypothesize that similar HBsAg reduction can be seen in hepatitis B virus (HBV) monoi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Price, Angie S., Nelson, Amy K., Ghosh, Alip, Kottilil, Shyamasundaran, Chua, Joel V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087219/ https://www.ncbi.nlm.nih.gov/pubmed/36045503 http://dx.doi.org/10.1002/jmv.28105

Ejemplares similares

Eight Weeks of Ledipasvir/Sofosbuvir in Kidney Transplant Recipients With Hepatitis C Genotype 1 Infection
por: Husson, Jennifer S., et al.
Publicado: (2017)

Effectiveness of 12 week ledipasvir/sofosbuvir and predictors of treatment failure in patients with hepatitis C
por: del Rio-Valencia, Juan Carlos, et al.
Publicado: (2019)

Ledipasvir‐Sofosbuvir for 12 Weeks in Children 3 to <6 Years Old With Chronic Hepatitis C
por: Schwarz, Kathleen B., et al.
Publicado: (2019)

Subgroup Differences in Response to 8 Weeks of Ledipasvir/Sofosbuvir for Chronic Hepatitis C
por: O'Brien, Thomas R., et al.
Publicado: (2014)

Reply: Subgroup Differences in Response to 8 Weeks of Ledipasvir/Sofosbuvir for Chronic Hepatitis C
por: O’Brien, Thomas R., et al.
Publicado: (2015)

Short‐duration treatment with the novel non‐nucleoside inhibitor CDI‐31244 plus sofosbuvir/velpatasvir for chronic hepatitis C: An open‐label study
por: Chua, Joel V., et al.
Publicado: (2020)

The Efficacy and Safety of 12 Weeks of Sofosbuvir and Ledipasvir versus Sofosbuvir, Ledipasvir, and Ribavirin in Patients with Chronic Hepatitis C, Genotype 1, Who Have Cirrhosis and Have Failed Prior Therapy: A Systematic Review and Meta-Analysis
por: Stokes, William, et al.
Publicado: (2017)

Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany
por: Stahmeyer, Jona T., et al.
Publicado: (2017)

Effectiveness of 8 or 12 Week Treatment Duration of Ledipasvir/Sofosbuvir for Hepatitis C: Evidence from a Large Academic Medical Center
por: Vega, Ana, et al.
Publicado: (2017)

New-Onset Diabetes Mellitus With Exposure to Ledipasvir and Sofosbuvir
por: Premji, Resmi, et al.
Publicado: (2015)

Palisaded neutrophilic and granulomatous dermatitis associated with ledipasvir/sofosbuvir
por: Shenk, Mary Elizabeth Reed, et al.
Publicado: (2018)

Efficacy of 8- versus 12-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C patients eligible for 8-week regimen in a real-world setting
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2019)

Clinical utility of ledipasvir/sofosbuvir in the treatment of adolescents and children with hepatitis C
por: Yang, Christine Hong Ting, et al.
Publicado: (2018)

Treatment with ledipasvir-sofosbuvir for hepatitis C resulting in improvement of lichen planus
por: Ansari, Umer, et al.
Publicado: (2017)

Treatment efficacy of ledipasvir/sofosbuvir for 8 weeks in non-cirrhotic chronic hepatitis C genotype 4 patients
por: Babatin, Mohammed A., et al.
Publicado: (2019)

Ledipasvir/Sofosbuvir for Patients Coinfected With Chronic Hepatitis C and Hepatitis B in Taiwan: Follow-up at 108 Weeks Posttreatment
por: Liu, Chun Jen, et al.
Publicado: (2021)

Efficacy of an 8-week course of sofosbuvir and ledipasvir for the treatment of HCV infection in selected HIV-infected patients
por: Ogbuagu, Onyema, et al.
Publicado: (2018)

Eight-Week Outcomes of Ledipasvir/Sofosbuvir in Noncirrhotic Treatment-Naive Patients with Hepatitis C: Analysis of Pharmacy-Based Data
por: Andres, Jennifer, et al.
Publicado: (2018)

Real‐world safety and efficacy of sofosbuvir and ledipasvir for elderly patients
por: Tamai, Hideyuki, et al.
Publicado: (2018)

Role of ledipasvir/sofosbuvir combination for genotype 1 hepatitis C virus infection
por: Sundaram, Vinay, et al.
Publicado: (2016)

Ledipasvir/Sofosbuvir Effectively Treats Hepatitis C Virus Infections in an Underserved Population
por: Stewart, Rachel A., et al.
Publicado: (2018)

Decreasing racial disparity with the combination of ledipasvir–sofosbuvir for the treatment of chronic hepatitis C
por: Naylor, Paul H, et al.
Publicado: (2017)

Quality of life of Japanese patients with chronic hepatitis C treated with ledipasvir and sofosbuvir
por: Younossi, Zobair M., et al.
Publicado: (2016)

Effectiveness of Ledipasvir/Sofosbuvir with/without Ribavarin in Liver Transplant Recipients with Hepatitis C
por: Saab, Sammy, et al.
Publicado: (2017)

Ledipasvir/Sofosbuvir Eradicates Hepatitis C in an Immunodeficient STAT3-GOF Patient
por: Thalhammer, Julian, et al.
Publicado: (2021)

Autoimmune Hepatitis During Ledipasvir/Sofosbuvir Treatment of Hepatitis C: A Case Report
por: Covini, Giovanni, et al.
Publicado: (2018)

Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany
por: Buggisch, Peter, et al.
Publicado: (2019)

Ledipasvir/sofosbuvir for treatment-naive and treatment-experienced Chinese patients with genotype 1 HCV: an open-label, phase 3b study
por: Wei, Lai, et al.
Publicado: (2018)

Effectiveness of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in People Who Inject Drugs and/or Those in Opioid Agonist Therapy
por: Janjua, Naveed Z., et al.
Publicado: (2019)

Real-world Effectiveness of Ledipasvir/Sofosbuvir (LDV/SOF) for 8 weeks in Patients Coinfected with HCV and HIV-1
por: Ruane, Peter, et al.
Publicado: (2017)

Blockade of CCR4 breaks immune tolerance in chronic hepatitis B patients by modulating regulatory pathways
por: Khanam, Arshi, et al.
Publicado: (2023)

Severe Steroid-responsive Skin Disorders Related to Ledipasvir and Sofosbuvir for HCV
por: Tadokoro, Tomoko, et al.
Publicado: (2017)

Ventricular Tachycardia as a Complication of Ledipasvir and Sofosbuvir Treatment for HCV Infection
por: Nirei, Kazushige, et al.
Publicado: (2017)

The effectiveness of oral antiviral (Sofosbuvir/Ledipasvir) in treating children with HCV infection
por: Alkaaby, Ban Adil, et al.
Publicado: (2018)

Drug-induced lung disease adverse effect with Ledipasvir Acetonate/Sofosbuvir
por: Omotani, Sachiko, et al.
Publicado: (2020)

Patient-reported Outcomes in Asian Patients With Chronic Hepatitis C Treated With Ledipasvir and Sofosbuvir
por: Younossi, Zobair M., et al.
Publicado: (2016)

Miliary tuberculosis infection during hepatitis C treatment with sofosbuvir and ledipasvir plus ribavirin
por: Ballester-Ferré, Maria Pilar, et al.
Publicado: (2017)

Ledipasvir and Sofosbuvir in the Treatment of Early Hepatitis C Virus Infection in HIV-Infected Men
por: Palaniswami, Paari M, et al.
Publicado: (2018)

The Influence of Treatment with Ledipasvir/Sofosbuvir on Growth Parameters in Children and Adolescents with Chronic Hepatitis C
por: Pokorska-Śpiewak, Maria, et al.
Publicado: (2022)

Ledipasvir/Sofosbuvir Is Effective as Sole Treatment of Porphyria Cutanea Tarda with Chronic Hepatitis C
por: Bonkovsky, Herbert L., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mkcbf4h286ruh787uk22vdk0vc